MetaVia Inc. (MTVA) 10-Year Financial Performance & Capital Metrics

MTVA • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesNASH & Liver Diseases

AboutMetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.Show more

Revenue $0
EBITDA -$29M -81.3%
Net Income -$28M -121.3%
EPS (Diluted) -3.56 -44.7%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -224.18% -245.5%
ROIC -
Debt/Equity 0.02 +40.9%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 99 (top 1%)

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 53.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-50.02%

EPS CAGR

10Y-

5Y-

3Y-

TTM0.31%

ROCE

10Y Avg-187.58%

5Y Avg-172.88%

3Y Avg-140.83%

Latest-232.24%

Peer Comparison

NASH & Liver Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MAZEMaze Therapeutics, Inc.	1.92B	39.81	511.70		31.18%	-33.24%	3.91%	0.14
GNFTGenfit S.A.	313.52M	6.27	209	134.56%	-14.12%	-31.42%	4.54%	0.90
GYREGyre Therapeutics, Inc.	741.77M	7.70	154	-6.78%	6.2%	4.84%		0.02
TVRDTvardi Therapeutics, Inc.	42.31M	4.51	-0.10	-65.96%	-317.54%	-63.46%
UNCYUnicycive Therapeutics, Inc.	134.75M	6.27	-1.12	-100%		-89.15%		0.10
GLTOGalecto, Inc.	38.32M	23.95	-1.29			-237.68%		0.00
IVAInventiva S.A.	1.17B	6.12	-1.73	-47.37%	-13.75%
AKBAAkebia Therapeutics, Inc.	355.59M	1.34	-4.06	-17.7%	-7.07%	-38.24%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	67K	72K	28K	7K	24K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	0	0	0	0	-67K	-72K	-28K	-7K	-24K
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	-	-0.07%	0.61%	0.75%	-2.43%
Operating Expenses+	8.08M	14.7M	33.12M	15.49M	20.18M	29.72M	15.3M	19.63M	15.89M	28.81M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	3.18M	5.96M	10.44M	1.6M	2.7M	7.85M	8.75M	8.64M	6.73M	7.26M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	3.99M	8.74M	22.69M	13.88M	17.48M	21.87M	6.55M	2.78M	9.16M	21.53M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	908K	0	0	0	0	0	0	8.21M	0	24K
Operating Income+	-8.08M	-14.7M	-33.12M	-15.49M	-20.18M	-29.72M	-15.3M	-19.63M	-15.89M	-28.81M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-29.36%	-0.82%	-1.25%	0.53%	-0.3%	-0.47%	0.49%	-0.28%	0.19%	-0.81%
EBITDA+	-7.17M	-14.7M	-33.12M	-15.49M	-20.16M	-29.67M	-15.25M	-19.61M	-15.88M	-28.79M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-25.95%	-1.05%	-1.25%	0.53%	-0.3%	-0.47%	0.49%	-0.29%	0.19%	-0.81%
D&A (Non-Cash Add-back)	0	0	0	0	17K	46K	48K	20K	6K	24K
EBIT	-7.17M	-14.7M	-33.12M	-15.49M	-20.18M	-29.72M	-15.28M	-11.78M	-15.89M	-28.81M
Net Interest Income+	-762K	114K	-286K	-40K	-22K	39K	14K	-2.19M	461K	920K
Interest Income	0	114K	0	0	0	39K	14K	0	461K	920K
Interest Expense	762K	0	286K	40K	22K	0	0	2.19M	0	0
Other Income/Expense	-953K	110K	-291K	-43K	-1.14M	38K	14K	5.66M	3.42M	1.22M
Pretax Income+	-9.03M	-14.59M	-33.41M	-15.53M	-21.31M	-29.68M	-15.28M	-13.97M	-12.47M	-27.59M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-9.03M	-14.59M	-33.41M	-15.53M	-21.31M	-29.68M	-15.28M	-13.97M	-12.47M	-27.59M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-27.22%	-0.62%	-1.29%	0.54%	-0.37%	-0.39%	0.49%	0.09%	0.11%	-1.21%
Net Income (Continuing)	-9.03M	-14.59M	-33.41M	-15.53M	-21.31M	-29.68M	-15.28M	-13.97M	-12.47M	-27.59M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-8525.49	-9677.67	-19380.00	-10260.00	-979.20	-439.20	-158.40	-43.44	-2.46	-3.56
EPS Growth %	-39.76%	-0.14%	-1%	0.47%	0.9%	0.55%	0.64%	0.73%	0.94%	-0.45%
EPS (Basic)	-8525.49	-9677.67	-19380.00	-10260.00	-979.20	-439.20	-158.40	-43.44	-2.46	-3.56
Diluted Shares Outstanding	1.53K	1.54K	1.72K	2.3K	21.77K	67.57K	96.43K	321.7K	5.07M	7.76M
Basic Shares Outstanding	1.53K	1.54K	1.72K	2.3K	21.77K	67.57K	96.43K	321.7K	5.07M	7.76M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	3.64M	24.75M	19.01M	3.81M	14.12M	10.68M	16.58M	33.53M	22.51M	16.07M
Cash & Short-Term Investments	3.62M	24.03M	18.47M	2.85M	13.91M	10.09M	16.39M	33.36M	22.43M	16.02M
Cash Only	3.62M	24.03M	18.47M	2.85M	13.91M	10.09M	16.39M	33.36M	22.43M	16.02M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	46K	34K	57K	48K	0	0	0	0
Total Non-Current Assets+	847K	8K	8K	12K	350K	285K	215K	2K	269K	188K
Property, Plant & Equipment	0	0	0	12K	350K	285K	215K	2K	248K	167K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	837K	8K	8K	0	0	0	0	0	21K	21K
Total Assets+	4.49M	24.75M	19.02M	3.82M	14.47M	10.97M	16.8M	33.53M	22.78M	16.26M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	11.9%	4.51%	-0.23%	-0.8%	2.79%	-0.24%	0.53%	1%	-0.32%	-0.29%
Total Current Liabilities+	8.92M	4.12M	6.39M	219K	2.08M	3.69M	2.16M	11.78M	5.96M	8.27M
Accounts Payable	531K	2.01M	4.03M	170K	638K	2.58M	830K	708K	821K	3.88M
Days Payables Outstanding	-	-	-	-	-	14.03K	4.21K	9.23K	42.81K	58.99K
Short-Term Debt	6.42M	0	1.35M	9.44M	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	347K	706K	306K	-9.42M	189K	40K	0	10.8M	942K	1.13M
Current Ratio	0.41x	6.00x	2.97x	17.39x	6.78x	2.89x	7.69x	2.85x	3.78x	1.94x
Quick Ratio	0.41x	6.00x	2.97x	17.39x	6.78x	2.89x	7.69x	2.85x	3.78x	1.94x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	7.95M	1K	8.69M	16.89M	94K	70K	45K	0	136K	58K
Long-Term Debt	0	0	8.68M	118K	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	23K	94K	70K	45K	0	136K	58K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	7.95M	1K	3K	16.75M	0	0	0	0	0	0
Total Liabilities	16.87M	4.12M	15.08M	17.11M	2.18M	3.77M	2.2M	11.78M	6.1M	8.33M
Total Debt+	6.42M	0	10.04M	9.58M	116K	94K	71K	0	203K	136K
Net Debt	2.8M	-24.03M	-8.44M	6.73M	-13.79M	-9.99M	-16.32M	-33.36M	-22.23M	-15.88M
Debt / Equity	-	-	2.55x	-	0.01x	0.01x	0.00x	-	0.01x	0.02x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-10.60x	-	-115.82x	-387.15x	-917.09x	-	-	-8.96x	-	-
Total Equity+	-12.38M	20.63M	3.94M	-13.29M	12.29M	7.2M	14.6M	21.75M	16.68M	7.93M
Equity Growth %	-22.31%	2.67%	-0.81%	-4.37%	1.93%	-0.41%	1.03%	0.49%	-0.23%	-0.52%
Book Value per Share	-8091.50	13354.05	2285.96	-5776.52	564.71	106.60	151.37	67.61	3.29	1.02
Total Shareholders' Equity	-12.38M	20.63M	3.94M	-13.29M	12.29M	7.2M	14.6M	21.75M	16.68M	7.93M
Common Stock	12K	17K	18K	0	16K	20K	1K	25K	5K	9K
Retained Earnings	-12.39M	-27.06M	-60.47M	-15.55M	-36.87M	-66.54M	-81.83M	-95.8M	-108.27M	-135.86M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	2K	12K	14K	4K	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-5.43M	-11.04M	-26.9M	-14.45M	-7.04M	-10.76M	-15.13M	-11.71M	-10.8M	-24.71M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-26.86%	-1.03%	-1.44%	0.46%	0.51%	-0.53%	-0.41%	0.23%	0.08%	-1.29%
Net Income	-9.03M	-14.59M	-33.41M	-15.53M	-21.31M	-29.68M	-15.28M	-13.97M	-12.47M	-27.59M
Depreciation & Amortization	0	0	0	0	17K	46K	48K	20K	6K	20K
Stock-Based Compensation	284K	1.72M	5.27M	0	118K	699K	662K	854K	222K	538K
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	1.87M	-93K	137K	1.86M	13.39M	17.36M	24K	2.55M	-2.95M	-293K
Working Capital Changes	1.45M	1.92M	1.1M	-778K	744K	809K	-584K	-1.17M	4.4M	2.62M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	444K	1.48M	2.01M	170K	-1.05M	1.12M	-1.16M	-202K	113K	3.06M
Cash from Investing+	0	0	0	-3K	-6.06M	69K	-586K	8K	-50K	-8K
Capital Expenditures	0	0	0	-3K	-214K	-4K	-3K	0	-50K	-8K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	-7.37M	-107K	-583K	8K	0	0
Cash from Financing+	8.74M	31.46M	21.34M	17.25M	24.17M	6.86M	22.03M	28.68M	-80K	18.3M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-202K	-3.97M	-1.2M	-25.2M	-73K	-642K	-1.97M	-35.82M	0	-1.7M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-5.43M	-11.04M	-26.9M	-14.45M	-7.25M	-10.77M	-15.14M	-11.71M	-10.85M	-24.72M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-26.86%	-1.03%	-1.44%	0.46%	0.5%	-0.48%	-0.41%	0.23%	0.07%	-1.28%
FCF per Share	-3550.98	-7147.57	-15603.83	-6284.35	-333.21	-159.36	-156.97	-36.41	-2.14	-3.19
FCF Conversion (FCF/Net Income)	0.60x	0.76x	0.81x	0.93x	0.33x	0.36x	0.99x	0.84x	0.87x	0.90x
Interest Paid	2K	0	291K	0	1K	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-353.51%	-271.97%	-	-173.38%	-304.47%	-140.22%	-76.85%	-64.89%	-224.18%
Debt / Equity	-	-	2.55x	-	0.01x	0.01x	0.00x	-	0.01x	0.02x
Interest Coverage	-10.60x	-	-115.82x	-387.15x	-917.09x	-	-	-8.96x	-	-
FCF Conversion	0.60x	0.76x	0.81x	0.93x	0.33x	0.36x	0.99x	0.84x	0.87x	0.90x

Frequently Asked Questions

Growth & Financials

MetaVia Inc. (MTVA) grew revenue by 0.0% over the past year. Growth has been modest.

MetaVia Inc. (MTVA) reported a net loss of $24.9M for fiscal year 2024.

Dividend & Returns

MetaVia Inc. (MTVA) has a return on equity (ROE) of -224.2%. Negative ROE indicates the company is unprofitable.

MetaVia Inc. (MTVA) had negative free cash flow of $21.3M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

MetaVia Inc. (MTVA) 10-Year Financial Performance & Capital Metrics

MTVA • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesNASH & Liver Diseases

Revenue $0
EBITDA -$29M -81.3%
Net Income -$28M -121.3%
EPS (Diluted) -3.56 -44.7%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -224.18% -245.5%
ROIC -
Debt/Equity 0.02 +40.9%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 99 (top 1%)

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 53.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-50.02%

EPS CAGR

10Y-

5Y-

3Y-

TTM0.31%

ROCE

10Y Avg-187.58%

5Y Avg-172.88%

3Y Avg-140.83%

Latest-232.24%

Peer Comparison

NASH & Liver Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MAZEMaze Therapeutics, Inc.	1.92B	39.81	511.70		31.18%	-33.24%	3.91%	0.14
GNFTGenfit S.A.	313.52M	6.27	209	134.56%	-14.12%	-31.42%	4.54%	0.90
GYREGyre Therapeutics, Inc.	741.77M	7.70	154	-6.78%	6.2%	4.84%		0.02
TVRDTvardi Therapeutics, Inc.	42.31M	4.51	-0.10	-65.96%	-317.54%	-63.46%
UNCYUnicycive Therapeutics, Inc.	134.75M	6.27	-1.12	-100%		-89.15%		0.10
GLTOGalecto, Inc.	38.32M	23.95	-1.29			-237.68%		0.00
IVAInventiva S.A.	1.17B	6.12	-1.73	-47.37%	-13.75%
AKBAAkebia Therapeutics, Inc.	355.59M	1.34	-4.06	-17.7%	-7.07%	-38.24%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	67K	72K	28K	7K	24K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	0	0	0	0	-67K	-72K	-28K	-7K	-24K
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	-	-0.07%	0.61%	0.75%	-2.43%
Operating Expenses+	8.08M	14.7M	33.12M	15.49M	20.18M	29.72M	15.3M	19.63M	15.89M	28.81M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	3.18M	5.96M	10.44M	1.6M	2.7M	7.85M	8.75M	8.64M	6.73M	7.26M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	3.99M	8.74M	22.69M	13.88M	17.48M	21.87M	6.55M	2.78M	9.16M	21.53M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	908K	0	0	0	0	0	0	8.21M	0	24K
Operating Income+	-8.08M	-14.7M	-33.12M	-15.49M	-20.18M	-29.72M	-15.3M	-19.63M	-15.89M	-28.81M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-29.36%	-0.82%	-1.25%	0.53%	-0.3%	-0.47%	0.49%	-0.28%	0.19%	-0.81%
EBITDA+	-7.17M	-14.7M	-33.12M	-15.49M	-20.16M	-29.67M	-15.25M	-19.61M	-15.88M	-28.79M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-25.95%	-1.05%	-1.25%	0.53%	-0.3%	-0.47%	0.49%	-0.29%	0.19%	-0.81%
D&A (Non-Cash Add-back)	0	0	0	0	17K	46K	48K	20K	6K	24K
EBIT	-7.17M	-14.7M	-33.12M	-15.49M	-20.18M	-29.72M	-15.28M	-11.78M	-15.89M	-28.81M
Net Interest Income+	-762K	114K	-286K	-40K	-22K	39K	14K	-2.19M	461K	920K
Interest Income	0	114K	0	0	0	39K	14K	0	461K	920K
Interest Expense	762K	0	286K	40K	22K	0	0	2.19M	0	0
Other Income/Expense	-953K	110K	-291K	-43K	-1.14M	38K	14K	5.66M	3.42M	1.22M
Pretax Income+	-9.03M	-14.59M	-33.41M	-15.53M	-21.31M	-29.68M	-15.28M	-13.97M	-12.47M	-27.59M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-9.03M	-14.59M	-33.41M	-15.53M	-21.31M	-29.68M	-15.28M	-13.97M	-12.47M	-27.59M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-27.22%	-0.62%	-1.29%	0.54%	-0.37%	-0.39%	0.49%	0.09%	0.11%	-1.21%
Net Income (Continuing)	-9.03M	-14.59M	-33.41M	-15.53M	-21.31M	-29.68M	-15.28M	-13.97M	-12.47M	-27.59M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-8525.49	-9677.67	-19380.00	-10260.00	-979.20	-439.20	-158.40	-43.44	-2.46	-3.56
EPS Growth %	-39.76%	-0.14%	-1%	0.47%	0.9%	0.55%	0.64%	0.73%	0.94%	-0.45%
EPS (Basic)	-8525.49	-9677.67	-19380.00	-10260.00	-979.20	-439.20	-158.40	-43.44	-2.46	-3.56
Diluted Shares Outstanding	1.53K	1.54K	1.72K	2.3K	21.77K	67.57K	96.43K	321.7K	5.07M	7.76M
Basic Shares Outstanding	1.53K	1.54K	1.72K	2.3K	21.77K	67.57K	96.43K	321.7K	5.07M	7.76M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	3.64M	24.75M	19.01M	3.81M	14.12M	10.68M	16.58M	33.53M	22.51M	16.07M
Cash & Short-Term Investments	3.62M	24.03M	18.47M	2.85M	13.91M	10.09M	16.39M	33.36M	22.43M	16.02M
Cash Only	3.62M	24.03M	18.47M	2.85M	13.91M	10.09M	16.39M	33.36M	22.43M	16.02M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	46K	34K	57K	48K	0	0	0	0
Total Non-Current Assets+	847K	8K	8K	12K	350K	285K	215K	2K	269K	188K
Property, Plant & Equipment	0	0	0	12K	350K	285K	215K	2K	248K	167K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	837K	8K	8K	0	0	0	0	0	21K	21K
Total Assets+	4.49M	24.75M	19.02M	3.82M	14.47M	10.97M	16.8M	33.53M	22.78M	16.26M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	11.9%	4.51%	-0.23%	-0.8%	2.79%	-0.24%	0.53%	1%	-0.32%	-0.29%
Total Current Liabilities+	8.92M	4.12M	6.39M	219K	2.08M	3.69M	2.16M	11.78M	5.96M	8.27M
Accounts Payable	531K	2.01M	4.03M	170K	638K	2.58M	830K	708K	821K	3.88M
Days Payables Outstanding	-	-	-	-	-	14.03K	4.21K	9.23K	42.81K	58.99K
Short-Term Debt	6.42M	0	1.35M	9.44M	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	347K	706K	306K	-9.42M	189K	40K	0	10.8M	942K	1.13M
Current Ratio	0.41x	6.00x	2.97x	17.39x	6.78x	2.89x	7.69x	2.85x	3.78x	1.94x
Quick Ratio	0.41x	6.00x	2.97x	17.39x	6.78x	2.89x	7.69x	2.85x	3.78x	1.94x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	7.95M	1K	8.69M	16.89M	94K	70K	45K	0	136K	58K
Long-Term Debt	0	0	8.68M	118K	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	23K	94K	70K	45K	0	136K	58K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	7.95M	1K	3K	16.75M	0	0	0	0	0	0
Total Liabilities	16.87M	4.12M	15.08M	17.11M	2.18M	3.77M	2.2M	11.78M	6.1M	8.33M
Total Debt+	6.42M	0	10.04M	9.58M	116K	94K	71K	0	203K	136K
Net Debt	2.8M	-24.03M	-8.44M	6.73M	-13.79M	-9.99M	-16.32M	-33.36M	-22.23M	-15.88M
Debt / Equity	-	-	2.55x	-	0.01x	0.01x	0.00x	-	0.01x	0.02x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-10.60x	-	-115.82x	-387.15x	-917.09x	-	-	-8.96x	-	-
Total Equity+	-12.38M	20.63M	3.94M	-13.29M	12.29M	7.2M	14.6M	21.75M	16.68M	7.93M
Equity Growth %	-22.31%	2.67%	-0.81%	-4.37%	1.93%	-0.41%	1.03%	0.49%	-0.23%	-0.52%
Book Value per Share	-8091.50	13354.05	2285.96	-5776.52	564.71	106.60	151.37	67.61	3.29	1.02
Total Shareholders' Equity	-12.38M	20.63M	3.94M	-13.29M	12.29M	7.2M	14.6M	21.75M	16.68M	7.93M
Common Stock	12K	17K	18K	0	16K	20K	1K	25K	5K	9K
Retained Earnings	-12.39M	-27.06M	-60.47M	-15.55M	-36.87M	-66.54M	-81.83M	-95.8M	-108.27M	-135.86M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	2K	12K	14K	4K	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-5.43M	-11.04M	-26.9M	-14.45M	-7.04M	-10.76M	-15.13M	-11.71M	-10.8M	-24.71M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-26.86%	-1.03%	-1.44%	0.46%	0.51%	-0.53%	-0.41%	0.23%	0.08%	-1.29%
Net Income	-9.03M	-14.59M	-33.41M	-15.53M	-21.31M	-29.68M	-15.28M	-13.97M	-12.47M	-27.59M
Depreciation & Amortization	0	0	0	0	17K	46K	48K	20K	6K	20K
Stock-Based Compensation	284K	1.72M	5.27M	0	118K	699K	662K	854K	222K	538K
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	1.87M	-93K	137K	1.86M	13.39M	17.36M	24K	2.55M	-2.95M	-293K
Working Capital Changes	1.45M	1.92M	1.1M	-778K	744K	809K	-584K	-1.17M	4.4M	2.62M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	444K	1.48M	2.01M	170K	-1.05M	1.12M	-1.16M	-202K	113K	3.06M
Cash from Investing+	0	0	0	-3K	-6.06M	69K	-586K	8K	-50K	-8K
Capital Expenditures	0	0	0	-3K	-214K	-4K	-3K	0	-50K	-8K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	-7.37M	-107K	-583K	8K	0	0
Cash from Financing+	8.74M	31.46M	21.34M	17.25M	24.17M	6.86M	22.03M	28.68M	-80K	18.3M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-202K	-3.97M	-1.2M	-25.2M	-73K	-642K	-1.97M	-35.82M	0	-1.7M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-5.43M	-11.04M	-26.9M	-14.45M	-7.25M	-10.77M	-15.14M	-11.71M	-10.85M	-24.72M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-26.86%	-1.03%	-1.44%	0.46%	0.5%	-0.48%	-0.41%	0.23%	0.07%	-1.28%
FCF per Share	-3550.98	-7147.57	-15603.83	-6284.35	-333.21	-159.36	-156.97	-36.41	-2.14	-3.19
FCF Conversion (FCF/Net Income)	0.60x	0.76x	0.81x	0.93x	0.33x	0.36x	0.99x	0.84x	0.87x	0.90x
Interest Paid	2K	0	291K	0	1K	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-353.51%	-271.97%	-	-173.38%	-304.47%	-140.22%	-76.85%	-64.89%	-224.18%
Debt / Equity	-	-	2.55x	-	0.01x	0.01x	0.00x	-	0.01x	0.02x
Interest Coverage	-10.60x	-	-115.82x	-387.15x	-917.09x	-	-	-8.96x	-	-
FCF Conversion	0.60x	0.76x	0.81x	0.93x	0.33x	0.36x	0.99x	0.84x	0.87x	0.90x

Frequently Asked Questions

Growth & Financials

MetaVia Inc. (MTVA) grew revenue by 0.0% over the past year. Growth has been modest.

MetaVia Inc. (MTVA) reported a net loss of $24.9M for fiscal year 2024.

Dividend & Returns

MetaVia Inc. (MTVA) has a return on equity (ROE) of -224.2%. Negative ROE indicates the company is unprofitable.

MetaVia Inc. (MTVA) had negative free cash flow of $21.3M in fiscal year 2024, likely due to heavy capital investments.